newsfilter
← Latest News
Business Wire·

Alzamend Neuro Submits IND Application for a Phase IIA Clinical Trial in Post-Traumatic Stress Disorder Patients of Next‑Generation Lithium Therapeutic Drug Candidate AL001

Alzamend's recently completed Phase IIA Study of AL001 in Alzheimer's patients and healthy subjects showed a benign safety profile and identified a candidate dose that is unlikely to require therapeutic drug